ArticleFrontiers in psychiatry2023

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression.

Johannes T Reckweg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.